Kamada Ltd. (KMDA)
| Market Cap | 447.24M +12.4% |
| Revenue (ttm) | 191.85M +13.2% |
| Net Income | 22.25M +17.0% |
| EPS | 0.36 +19.0% |
| Shares Out | 57.89M |
| PE Ratio | 21.34 |
| Forward PE | 17.24 |
| Dividend | $0.42 (5.46%) |
| Ex-Dividend Date | Aug 27, 2026 |
| Volume | 47,507 |
| Open | 7.88 |
| Previous Close | 7.95 |
| Day's Range | 7.67 - 7.88 |
| 52-Week Range | 6.55 - 9.35 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 13.50 (+75.33%) |
| Est. Earnings | Nov 13, 2026 |
About KMDA
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Financial Performance
In 2025, Kamada's revenue was $180.46 million, an increase of 12.12% compared to the previous year's $160.95 million. Earnings were $20.20 million, an increase of 39.66%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 75.33% from the latest price.
News
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada launches two new biosimilar products in Israel
Kamada (KMDA) announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products. The two…
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Mi...
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand ...
Kamada Transcript: Small-Cap Virtual Conference
Double-digit growth continues, with 2026 revenue and EBITDA on track and strong cash generation. Specialty plasma therapies, expanded distribution, and a robust product portfolio drive performance, while new plasma sales agreements and M&A opportunities support future growth.
Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase
(RTTNews) - Kamada Ltd. (KMDA; KMDA.TA) confirmed that it maintains sufficient inventory and manufacturing capacity to meet increased U.S. demand for KedRAB, following a September 10, 2026 Health Advi...
Kamada confirms sufficient KedRAB supply amid increased demand
Kamada (KMDA) confirmed that it maintains sufficient KedRAB supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory ...
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-A...
Kamada Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Double-digit growth continues with $200–$205 million in projected 2024 sales and strong profitability. Expansion is driven by a diverse plasma-derived product portfolio, biosimilar launches, international reach, and a $50 million plasma sales contract, with M&A opportunities under review.
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...
Kamada Registration statement: Registration filing
Kamada filed a registration statement on September 9, 2026, providing details about a securities offering with the SEC.
Kamada files to sell $50M of ordinary shares
07:07 EDT Kamada (KMDA) files to sell $50M of ordinary shares
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed product...
KMDA Ex-Dividend Reminder - 8/27/26
Looking at the universe of stocks we cover at Dividend Channel, on 8/27/26, Kamada Ltd (Symbol: KMDA) will trade ex-dividend, for its annual dividend of $0.17, payable on 9/17/26. As a percentage of K...
Kamada (KMDA) Q2 2026 Earnings Call Transcript
KEDRAB sales and distribution expansion drive record revenue and EBITDA growth.
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
Kamada CFO Chaime Orlev to depart
Kamada (KMDA) announced that Chaime Orlev, its CFO, will transition out of his role to pursue other opportunities, effective December 31. Kamada has a search underway to identify a successor…
Kamada reports Q2 EPS 16c, consensus 11c
Reports Q2 revenue $54.92M vs. $44.75M last year. “We continue to execute on our plan delivering record-high operational and financial performance during the first half of 2026, with strong double-dig...
Kamada backs FY26 revenue view $200M-$205M
The company said, “Kamada (KMDA) is reiterating its 2026 annual financial guidance of total revenues in the range of $200 million to $205 million, and adjusted EBITDA in the range…
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Kamada Q2 Earnings Call Highlights
Kamada NASDAQ: KMDA reported record revenue and adjusted EBITDA for the second quarter and first half of 2026, driven by higher sales of its specialty plasma-derived products, including KEDRAB, VARIZI...
Kamada Q2 2026 EPS Tops Expectations, Revenue Up 23%
Strong beat. Kamada Ltd. (NASDAQ:KMDA) delivered Q2 2026 adjusted earnings of $0.24 per share, more than doubling the $0.11 consensus estimate in a beat by ... The post Kamada Q2 2026 EPS Tops Expecta...
Kamada Earnings Call Transcript: Q2 2026
Record first-half 2026 results with double-digit revenue and EBITDA growth, driven by strong U.S. and international sales, expanding plasma operations, and disciplined cost management. Guidance for 2026 is reiterated, with continued double-digit growth expected.
Kamada Earnings release: Q2 2026
Kamada released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Kamada Releases Q2 2026 Financial Results
Kamada Ltd. The post Kamada Releases Q2 2026 Financial Results first appeared on Alphastreet .